Ispire Technology Inc. ISPR
Medicinal Chemicals and Botanical Products · IPO 2023 · data as of November 13, 2026
Ispire Technology Inc. (ISPR) is a healthcare company listed in the US with a market value of about $98M. In the twelve months to September 30, 2026 it had revenue of $93M and net income of -$36M, a net margin of -39.0%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -142%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 89% below the current price.
About Ispire Technology
Ispire Technology is listed in the US and classified in medicinal chemicals and botanical products, IPO year 2023. Revenue went from $88M in 2022 to $96M in 2026, growth of about 2.2% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 13% over three years (dilution for shareholders). It spends 0% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Revenue | $93M | $96M | $127M | $152M | $116M | $88M |
| Net income | -$36M | -$33M | -$39M | -$15M | -$6M | -$2M |
| Free cash flow | -$1M | -$875368 | -$8M | -$20M | -$9M | -$8M |
| EPS (diluted) | $-0.64 | $-0.58 | $-0.69 | $-0.27 | $-0.12 | $-0.04 |
| Net margin | -39.0% | -34.6% | -30.8% | -9.7% | -5.2% | -2.1% |
| ROIC | — | — | -523.6% | -29.0% | -10.0% | -6.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Ispire Technology stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 89% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ispire Technology pay a dividend?
Not currently.
Is Ispire Technology a good stock to buy?
We do not give buy or sell advice. Ispire Technology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.